Vertex Pharmaceuticals Waits to Hit the Triple

Vertex Pharmaceuticals (NASDAQ:VRTX) continues to post substantial revenue growth, although many investors are rightfully looking ahead to its next-generation triple combinations for cystic fibrosis.